Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Revvity Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.42 (market cap $41.13B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 2.4× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Revvity Inc for 12 Days on average.
| IEF | RVTY | |
|---|---|---|
Market Cap | $41.13B | $16.98B |
Volume | 10,340,382 | 1,456,900 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $157.36 |
52-Week Low | $88.92 | $82.26 |
Typical Hold Time | 108 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.40, up 0.33% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with key support at $89 and resistance at $90. Recent dividend payments of $0.31-$0.33 per share provide income, while financial ratios remain unavailable. Market sentiment reflects defensive positioning amid Treasury yield volatility.
Outlook remains cautious due to technical bearishness and bond market pressures. Opportunities include income from dividends and potential stability in defensive portfolios. Risks include continued bond market volatility and macroeconomic uncertainty affecting Treasury yields.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
